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Abstract
Despite the ferment aroused in the scientific community by the COVID-19 outbreak and the over 11,000 
papers listed in PubMed, published evidence on safe and effective drugs has not progressed yet at the 
same speed of the pandemic. However, clinical research is rapidly progressing, as shown by the hundreds 
of registered clinical trials on candidate drugs for COVID-19. Unfortunately, information on protocols of 
individual studies differs from registry to registry. Furthermore, study designs, criteria for stratification of 
patients and choice of outcomes are quite heterogeneous. All this makes data sharing and secondary 
analysis difficult.At last, small single centre studies and the use of drugs on a compassionate basis should 
be replaced by highly powered, multi-centre, multi-arm clinical trials, in orderto provide the required 
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Hopefully, the efforts of clinical researchers in the fight against the SARS Cov-2 will result into the 
identification of effective treatments. To make this possible, clinical research should be oriented by 
guidelines for more harmonized high-quality studies and by a united commitment of the scientific 
community to share personal knowledge and data. Allergists and clinical immunologists should have a 
leading role in this unprecedent challenge.
Introduction
Covid-19 has aroused an unprecedented scientific ferment to tackle this deadly pandemic. The most 
important scientific journals, including Allergy, have created a specific section on COVID-19. As of May 12, 
day of submission, a PubMed search for COVID-19 shows11,336papers published in 2020 (almost 10 every 
working hour).However, this number increasesas rapidly as the number of worldwide infected people and 
deaths reported daily by the WHO and the national authorities. Through this emerging literature, much 
has been learned on the mechanisms of SARS CoV-2 infection1,2, modes of transmission, incubation 
period, clinical features, incidence and lethality of the disease3,4. 
Following initial discordantstrategies in different countries5, there has also been general agreement on 
the efficacy of the lockdown in China and the strict public health measuresfirstly implemented in Europe 
by the Italian government to suppress COVID-19 diffusion (isolation of areas with a high number of 
positive cases, closure of non-essential public places, schools and universities, cancellation of congresses 
and mass gathering events). Recommendations made by governmentsfor a lockdown – although 
implemented at different times -appear to be fully justified and supported by accurate modelling on their 
potential effect on the mitigation or suppression of the infection6.
On the other hand, the search for an effective therapy of COVID-19 is still a work in progress, which 
demands a harmonized approach of the scientific community. This article aims to provide a critical 
overview of the clinical trials exploring candidate drugs for potential treatment for COVID-19. The several 
ongoing clinical trials on SARS-CoV-2 vaccines do not fall within the scope of this article.
The leading role of allergists and clinical immunologists in the fight against SARS CoV-2
There is no doubt that allergists and clinical immunologists should be on the front line in the fight against 
SARS CoV-2, since their expertise is required for a better understanding of COVID-19pathophysiology and 
its management.First, the host immune response is the main mechanism to block the viral infection and 
attenuate or prevent symptoms7. Second, there is a wide consensus that the progression of the disease to 
the most severe life-threatening forms is associated with an intense inflammatory process and a cytokine 
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are part of the current therapeutic armamentarium of the clinical immunologist and require the expertise 
of our specialty8.
In fact, 39 clinical trials explore the efficacy of Tocilizumab, an anti-IL-6R (sIL-6R and mIL-6R) monoclonal 
antibody widely used by allergists and clinical immunologists for the treatment of rheumatoid arthritis, 
giant cell arteritis and the CAR-T induced Cytokine Release Syndrome9. Some other candidate monoclonal 
antibodies for COVID-19 clinical trials - targeting IL-1, IL-17A, growth factors, complement factors -, are 
listed in Table I.
Beside monoclonal antibodies, several other immunosuppressants and immunomodulators are under 
investigation9. Interferon beta 1a – both intravenously and in an inhaled formulation -, interferon alfa 2a 
and peginterferon lamda 1A are object of 31 clinical studies. Immunoglobulin and convalescent plasma-
based therapy are investigated in 60trials. 
Twenty-three registered studies9are evaluating the use of systemic corticosteroids in COVID-19. Despite 
concern about possible detrimental effects10,11, there is yet no evidence for or against their use in COVID-
19 patients. There is rational to speculate that their safety and efficacy may be different in the early viral 
phase compared to the late inflammatory phase. Conversely, there is no evidence to withdraw an ongoing 
treatment with inhaled steroids in subjects with asthma and rhinitis12,13.
Other immunomodulatory/immunosuppressive drugs and the effect of cytokine filtration devices are also 
under investigation, particularly in COVID-19 subjects with pneumonia and a severe inflammatory 
disease8.
More studies on anti-TNF drugs have been recommended14. Among cell-based therapies, 24 studies plan 
to investigate the immunomodulatory role of mesenchymal stem cells8. 
However, despite this intense clinical research and236 papers (including 4 systematic reviews) on COVID-
19 treatment listed by PubMed, evidence available for safe and effective drugs has not progressed at the 
same speed of the pandemic15.In fact, to our knowledge only very few clinical trials have been published.
The randomized, open-label trial with Lopinavir/Ritonavir in 199 patients with severe COVID-19 failed to 
meet the primary end-point (time to clinical improvement)16. However, 70additional studies are 
investigating the efficacy of Lopinavir/Ritonavir in various severity stages of the disease9. 
Following the more promising results of a cohort study of patients treated with Remdesivir on a 
compassionate-use17, both FDA and EMA have permitted the use of this drug in COVID-19 clinical trials. 
While a randomized double-blind placebo-controlled trial could not confirm a significant benefit of 
Remdesivir in a cohort of 236 patients – possibly because of the failure to recruit its target of 453 
patients18 -, it has been recently anticipated that a larger multi-centre trial in over 1000 subjects showed a 
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reduced from 15 to 11 days)19.Eleven more trials on Remdesivirare still ongoing9. A few additional 
published studies with hydroxichloroquine vs best supportive care, favipiravir vs umifenovir, and 
lopinavir/ritonavir vs umifenovir are reported by Thorlund and co-workers20.
COVID-19 registries and drug pipeline
However, clinical research is rapidly expanding and hundreds of clinical trials have been registered 
including, beside immunologic drugs, anti-viral drugs, protein-kinase inhibitors, anti-inflammatory drugs, 
or drugs aimed at facing the most severe symptoms of COVID-19, such as anti-coagulants, anti-infective 
drugs, drugs for the cardiovascular, respiratory and nervous systems (Table 2).
The WHO registry21(ICTRP) included, at April 29,1524 studies, whose details are not easily accessible. The 
registry, due to the heavy traffic generated by the COVID-19 outbreak is temporarily not accessible from 
outside the WHO.
US NIH Clinicaltrials.gov22 lists1409trials, including830 interventional studies; only 20of these trials have 
been completed, but results have not been published yet.
EudraCT23includes175clinical trials,all still ongoing. 
Cytel, a Global Coronavirus COVID-19 clinical trials tracker, funded in part by the Bill& Melinda Gates 
Foundation9, lists 1029 clinical trials, 340 from China and 51dealing with traditional Chinese medicinal 
products. Most interventional studies evaluate the effects ofhydroxychloroquine or chloroquine (218 
studies), lopinavir/ritonavir (70studies), plasma-based therapy (60 studies), and tocilizumab (39studies). 
Only8studies are already completed with results (7 from Chinaand 1 from France) but only one has have a 
randomizeddouble-blind study design. 
The comparative review of registries allows some critical considerations.
There is a substantial discrepancy in the number of studies reported in different registries and it is quite 
difficult to identify duplicates among registries or studies listed in some registries but not in others.
Furthermore, the available information for individual studies differs from registry to registry and is not 
easily extractable. At last, protocols of studies are not accessible in most registries. Thus, it is highly 
appreciable the initiative of tracking and collating clinical trials in a single registry, also using artificial 
intelligence-based methods for data search and aggregator services20.This approachwill alloweasier data 
sharing among investigators and analysis of pooled data.
Data sharing and secondary analysis represent valuable tools to advance knowledge and help regulatory 
decisions. Transparency policies have been recently adopted in Europe by the European Medicines 
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several international institutions26 and by the International Committee of Medical Journal Editors27. Data 
sharing appears fundamental in health emergencies, such as COVID-19 outbreak, to implement rapid and 
effective responses. Several platforms are available for data storage and analysis also offering protocol 
assistance and free anonymization of data from subjects with COVID-1928.
The need for a standardized approach in COVID-19 clinical research
However, in order to make feasible secondary analysis of individual studies, these should follow 
guidelines for standard protocols and minimal requirements for outcome measures such as the Standard 
Protocol Items Recommendations for Interventional Trials (SPIRIT)29 and the Core Outcome Measures in 
Effectiveness Trials (COMET) initiative30.
In fact, the major criticism emerging from a review of the ongoing trials is theheterogeneity of protocols. 
Following the decision of both FDA and EMA,respectively, to allow the use of chloroquine or 
hydroxichloroquine and remdesivirfor clinical trials inCOVID-1931,32,several small trials have started using 
these drugs on a compassionate basis. The EMA hasexpressed concern for these small studies andthe 
compassionate use programmes across Europe, as they are unlikely to produce the required level of 
evidence of efficacy and safety of investigational drugs. On the contrary, the EMA strongly recommends 
that a more coordinated approach and efforts are putin place to prioritize large multi-country randomized 
trials and multi-arm clinical trials investigating different agents simultaneously33.In order to generate 
robust evidence on efficacy and safety of drugs and vaccines for COVID-19,EMA offersfree scientific advice 
on the best methods and designs to be usedin clinical trials34.
Unarguably, high quality clinical trials cannot be easily performed in the setting of an outbreak, when 
investigators are often asked to make patients’ care a priority. Nonetheless, even if adapted to this 
challenging context, high quality research is still needed35. Accordingly, a more standardized approach to 
clinical research on COVID-19 should be warranted, including a rigorous but realistic study design, a well 
characterized study population stratified on the basis of age and severity of the disease, a rationale 
behind the use of the investigational drug and the choice of comparator, and optimal minimal primary 
outcome(s).
With regard to the study design, while masking might be difficult in studies of COVID-19, randomization 
should be mandatory. Multi-centre trials are highly advisable provided that standard operational 
procedures are set out. Adaptive designs might beconsidered and the setting should be specified. Rules 
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might favour a more rapid start of the trial. Investigators should be encouraged to publish the study 
protocol to be drafted according to the SPIRIT29and COS-STAP statement36.
Age, gender, ethnicity, previous diseases and undergoing treatments of the selected population have 
been reported to influence the incidence of COVID3,4,37-39. Demographic and history data should be 
obtained, possibly through a standard questionnaire, along with other patients’ characteristics such as 
social status and environmental exposure. 
While waiting for a consensus on criteria for the diagnosis of COVID-19 and a classification of the disease, 
patients should be stratified on the basis of the study setting, severity, and the predominant 
pathophysiological abnormality in different phases of the disease (viral, pulmonary, inflammatory; 
Fig.1)40.
Several research groups are working on a variety of preventive and therapeutic interventions. However, 
despite the accelerated development pathways adopted by many regulatory bodies41, the marketing 
authorization pathway for new drugs is a long process, with a high attrition rate. Therefore, there has 
been considerable interest in repurposing existing drugs – such as antiviral and immunosuppressant 
agents - for use in COVID-198. Studies with these drugs should keep in consideration the putative 
mechanisms of action of the investigational drug in relation to the different phases of COVID-19. Antiviral 
agents, for example, should be used during the early viral phase of the disease while immunosuppressant 
may be promising candidate drugs in the severe inflammatory phase (while they might dampen the 
immune response if used early on15). Combination or sequential treatment might also be considered.
An interesting alternative strategy for drugs repurposing in COVID-19 is represented by a structural 
analysis of available medicines with potential inhibitory effects on molecules involved in SARS-CoV-2 
infection and replication1,2. In an in-silico molecular modelling screening of 2000 FDA approved drugs for 
potential inhibitory effect on SARS CoV-2 main protease enzyme (Mpro), the top hits bound to the central 
site of Mpro substrate-binding pocket included antiviral drugs such as Darunavir, Nelfinavir and 
Saquinavir.Interestingly, the top hits bound to the terminal site of Mpro substrate-binding pocket 
included Montelukast and Fexofenadine42. Independently from the practical impact of the above 
observation, this strategy appears promising in repositioning available drugs, until novel targeted 
treatments for COVID-19 are available.
Standard of care seems to be a more realistic comparator than placebo, in view of the emergency nature 
of the epidemic.
Collaborative trials and multi-arm studies comparing different drugs should also be considered.A 
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the WHO43.The Solidarity trial is a randomized multi-countries open label trial which compares the 
efficacy of four treatment options (Remdesivir, Lopinavir/Ritonavir, Interferon beta-1a and Chloroquine or 
Hydroxychloroquine) against standard of care in hospitalized adult patients with COVID-19. Underlying 
conditions are recorded and severity of illness at entry is determined bya reduced set of end-points that 
can be recorded even in overwhelmed hospitals. Clinically relevant outcomes undergo an interim analysis 
by an independent Global Data and Safety monitoring Committee. The simplicity of the trial is balanced by 
the thousands of patients that are expected to be recruited in more than 70 countries. Preliminary results 
of this trial are expected by June 2020.
In more rigorous study designs, primary outcome measures should be chosen in relation to the phase of 
the disease and the drug under investigation. While SARS CoV-2 RNA clearance and the effects on the 
progression of the disease may represent significant outcome measures for antivirals in the mild forms of 
the disease, hard end-points such survival/death are advisable in the most severe forms.However, a core 
outcome standard set is urgently needed to define a minimal set of outcome measures relevant to 
patients, investigators and regulators44.
Conclusions
Hopefully, the efforts of clinical researchers in the fight against the SARS Cov-2 will result into the 
identification of effective treatments. This would largely counterbalance the delaying effectsof COVID-on 
ongoing trials for other diseases45.However, these efforts might be negatively affected in the absence of 
guidelines for a more harmonized clinical research and a united commitment of the scientific community 
to share personal knowledge and data. Allergists and clinical immunologists should have a leading role in 
this unprecedent challenge.
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Figure 1. Staging of COVID-19.  Clinical features, management and candidate therapeutic options. 
Modified from Ref. 40 and 47.
Legenda: ICU = Intensive Care Unit;  SatO2 = Oxigen saturation; RR = Respiratory Rate; PaO2/FiO2 = ratio 
of arterial oxygen partial pressure (PaO2, in mmHg) to fractional inspired oxygen (FiO2, expressed as a 
fraction); ARDS = Acute respiratory Distress Syndrome; PCR = Polymerase Chain Reaction; CBC = Complete 
Blood Count; CRP = C Reactive Protein; HFNC = High Flow Nasal Cannula; NIPPV = Non-Invasive Positive 
Pressure Ventilation; MSC = Mesenchimal Stem Cells; ABG = Arterial Blood Gas; MOF = Multi-organ failure; 
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